Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.51 |
| ▸ | HSPA9 | P38646 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.43 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750648 | 0.88 | HSPA9 (0.56) | EPHX2HSPA9CA12CA1CA2 | |
| SCHEMBL21750693 | 0.87 | TRPV1 (0.47) | EPHX2HSPA9CA12CA1CA2 | |
| SCHEMBL21750814 | 0.87 | HSPA9 (0.47) | EPHX2HSPA9CA12CA1CA2 | |
| SCHEMBL21750734 | 0.85 | EPHX2 (0.54) | EPHX2HSPA9MEN1MAPTHTT | |
| SCHEMBL26722472 | 0.82 | BACE1 (0.39) | HSPA9TRPV1MEN1MAPTRAB9A | |
| SCHEMBL21750751 | 0.81 | MAPT (0.49) | EPHX2HSPA9CA12CA1CA2 | |
| SCHEMBL21750752 | 0.78 | TRPV1 (0.47) | EPHX2HSPA9CA12CA1CA2 | |
| SCHEMBL26472206 | 0.78 | MAPT (0.61) | CA12CA1CA2CA9TRPV1 | |
| SCHEMBL21750767 | 0.77 | RARA (0.60) | EPHX2HSPA9CA12CA1CA2 | |
| SCHEMBL4053608 | 0.76 | EPHX2 (0.61) | EPHX2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947198-B2 | Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-03-16 | — | — | US | claimed |
| US-20200062711-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2020-02-27 | — | — | US | claimed |
| US-11993573-B2 | Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2024-05-28 | — | — | US | disclosed |
| US-20210163415-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-06-03 | — | — | US | disclosed |
| US-10947198-B2 | Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200062711-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163415-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | HCCS, CDYL, XPOT | EPHX2 2750/4885HSPA9 2213/4885CA12 3300/4885 |
| US-10947198-B2 | Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents | HCCS, CDYL, XPOT | EPHX2 2750/4885HSPA9 2213/4885CA12 3300/4885 |
| US-11993573-B2 | Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents | HCCS, CDYL, CDYL2 | EPHX2 2450/4885HSPA9 3140/4885CA12 2771/4885 |
| US-20200062711-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | HCCS, CDYL, XPOT | EPHX2 2750/4885HSPA9 2213/4885CA12 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.